FLT3 ITD Allelic Ratio Test: Comprehensive Genetic Analysis for Leukemia Diagnosis
Understanding the FLT3 ITD Allelic Ratio Test
The FLT3 ITD Allelic Ratio test represents a breakthrough in molecular diagnostics for hematologic malignancies, specifically targeting acute myeloid leukemia (AML). This sophisticated genetic analysis examines the FLT3 gene, which encodes a tyrosine kinase receptor crucial for normal blood cell development. When internal tandem duplications (ITD) occur in this gene, they create abnormal signaling pathways that drive uncontrolled leukemia cell growth.
What makes this test particularly valuable is its ability to quantify the allelic ratio – the proportion of mutant FLT3 alleles compared to normal wild-type alleles. This ratio provides critical prognostic information that directly influences treatment strategies and patient outcomes. The test’s precision in detecting and measuring these genetic alterations has revolutionized how oncologists approach AML management.
What the FLT3 ITD Allelic Ratio Test Measures
This advanced diagnostic test specifically detects and quantifies:
- FLT3 Internal Tandem Duplications (ITD): Identifies abnormal duplications within the FLT3 gene’s juxtamembrane domain
- Allelic Ratio Calculation: Precisely measures the ratio of mutant FLT3 alleles to wild-type alleles
- Mutation Burden Assessment: Determines the extent of FLT3 mutation presence in the patient’s hematopoietic cells
- Genetic Heterogeneity: Evaluates the diversity of FLT3 mutations within the leukemia cell population
Who Should Consider FLT3 ITD Allelic Ratio Testing
Primary Candidates for Testing
- Newly Diagnosed AML Patients: Essential for initial risk stratification and treatment planning
- Patients with Treatment-Resistant Leukemia: Helps identify potential FLT3 inhibitor therapy candidates
- Individuals with Recurrent Leukemia Symptoms: Unexplained fatigue, frequent infections, or abnormal bleeding
- Patients with High-Risk Genetic Profiles: Those with other leukemia-associated genetic abnormalities
- Pre-Transplant Evaluation Candidates: Critical for determining transplant eligibility and timing
Clinical Indications
Patients experiencing symptoms such as persistent fatigue, unexplained bruising, recurrent infections, bone pain, or abnormal blood counts should discuss FLT3 testing with their hematologist. The test is particularly important for individuals with confirmed or suspected acute myeloid leukemia who require comprehensive genetic profiling for optimal treatment selection.
Benefits of FLT3 ITD Allelic Ratio Testing
- Precision Treatment Guidance: Identifies patients who may benefit from targeted FLT3 inhibitor therapies
- Accurate Risk Stratification: Provides crucial prognostic information for treatment intensity decisions
- Early Intervention Opportunities: Enables timely implementation of appropriate therapeutic strategies
- Personalized Medicine Approach: Supports development of individualized treatment protocols
- Monitoring Disease Progression: Allows tracking of mutation status during treatment and remission
- Improved Survival Outcomes: Contributes to better long-term prognosis through targeted therapy selection
Understanding Your FLT3 ITD Allelic Ratio Results
Interpretation Guidelines
Your FLT3 ITD Allelic Ratio results will provide critical information about your leukemia’s genetic characteristics:
- Low Ratio Results (<0.5): Indicate lower mutation burden, typically associated with standard-risk AML classification
- High Ratio Results (>0.5): Suggest significant mutation presence, often correlating with high-risk disease and poorer prognosis
- Negative Results: No FLT3-ITD mutations detected, indicating alternative genetic drivers of leukemia
- Complex Mutation Patterns: Multiple ITD variants may suggest more aggressive disease biology
Clinical Implications
High allelic ratios typically indicate the need for more intensive treatment approaches, including consideration of FLT3 inhibitor therapies such as midostaurin or gilteritinib. Your hematologist will integrate these results with other diagnostic findings to create a comprehensive treatment plan tailored to your specific genetic profile.
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| FLT3 ITD Allelic Ratio Test – Discount Price | $188 |
| FLT3 ITD Allelic Ratio Test – Regular Price | $250 |
Test Specifications
- Turnaround Time: 8-10 days
- Sample Type: Bone marrow / Peripheral blood (Transport immediately)
- Test Components: EDTA Vacutainer (2ml)
- Methodology: Fragment Analysis
Nationwide Availability and Booking
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, Charlotte, San Francisco, Indianapolis, Seattle, Denver, Washington DC, Boston, El Paso, Nashville, Detroit, Oklahoma City, Portland, Las Vegas, Memphis, Louisville, Baltimore, and Milwaukee.
Our state-of-the-art laboratories utilize advanced fragment analysis technology to ensure the highest accuracy in FLT3 ITD detection and allelic ratio calculation. Each test is performed by experienced genetic specialists following rigorous quality control protocols.
Take Action for Your Health
Don’t wait to get the critical genetic information you need for optimal leukemia management. Our FLT3 ITD Allelic Ratio test provides essential data that can significantly impact your treatment journey and long-term outcomes.
Book your FLT3 ITD Allelic Ratio test today by calling our dedicated healthcare line at +1(267) 388-9828 or schedule your appointment online. Our genetic counseling team is available to discuss your testing needs and answer any questions about the procedure and results interpretation.
Remember: Early and accurate genetic testing can make a substantial difference in leukemia treatment success. Take the first step toward personalized cancer care with comprehensive FLT3 analysis.
